Press release
Vasomotor Symptoms Market to Reach USD 12.1 Billion by 2034
Vasomotor Symptoms
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/49980
Key Takeaways
• Market Size (2024): USD 7.4 billion
• Forecast (2034): USD 12.1 billion
• CAGR (2025 - 2034): 5.0 %
• Major Companies: Astellas Pharma Inc., Bayer AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Johnson & Johnson Services Inc., Eli Lilly and Company, Amgen Inc., Abbott Laboratories, TherapeuticsMD Inc., and Novo Nordisk A/S.
• Key Therapeutic Areas: Hormone Replacement Therapy (HRT), Selective Estrogen Receptor Modulators (SERMs), Neurokinin-3 Receptor Antagonists, and Herbal/Nutraceutical Supplements.
Market Story
Vasomotor symptoms - including hot flashes and night sweats - are among the most common and disruptive effects of menopause, affecting nearly 80 % of women globally. With increasing longevity and a growing emphasis on women's quality of life, the demand for safe, effective, and personalized symptom-management therapies continues to climb.
The market is witnessing strong adoption of non-hormonal therapies such as Neurokinin-3 receptor antagonists (e.g., fezolinetant) and plant-based formulations, especially among women seeking alternatives to hormone replacement therapy. Pharmaceutical innovation, telehealth menopause clinics, and rising healthcare investments are redefining the landscape of women's midlife care.
Market Segmentation
• By Therapy Type: Hormonal (Estrogen, Progestin, Combination) | Non-Hormonal (NK3 Receptor Antagonists, SSRIs, Herbal/Nutraceuticals)
• By Route of Administration: Oral | Transdermal | Injectable | Topical
• By Distribution Channel: Hospital Pharmacies | Retail Pharmacies | Online Platforms | Specialty Clinics
• By Region:
o North America: Largest market; early adoption of FDA-approved non-hormonal therapies and digital health platforms.
o Europe: Rising research activity and healthcare awareness campaigns on menopause management.
o Asia Pacific: Fastest growth driven by expanding women's-healthcare infrastructure in Japan, India, and South Korea.
o Latin America & MEA: Increasing use of OTC herbal and nutraceutical products for symptom relief.
Explore Full Report here: https://exactitudeconsultancy.com/reports/49980/vasomotor-symptoms-market
Recent Developments
• 2025: Astellas Pharma launched VeozahTM (fezolinetant) across new markets following FDA approval for moderate to severe vasomotor symptoms.
• 2024: Bayer AG partnered with digital menopause-tracking platforms to integrate therapy adherence data analytics.
• 2023: Pfizer initiated Phase III trials for its next-generation non-hormonal NK3 receptor antagonist.
• 2022: TherapeuticsMD expanded its telemedicine-based menopause care network in North America.
Expert Quote
"Menopause care is moving from stigma to science. Personalized non-hormonal therapies and digital support platforms are helping women manage vasomotor symptoms more safely and confidently," said Irfan Tamboli, Business Development Executive at Exactitude Consultancy.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=49980
Market Drivers
1. Growing Global Menopausal Population with longer post-reproductive lifespans.
2. Shift Toward Non-Hormonal and Personalized Medicine.
3. Increased Awareness Through Digital Health and Education Campaigns.
4. Regulatory Approvals and Strong R&D Pipeline for Novel NK3 Antagonists.
Forecast Outlook
Between 2025 and 2034, the vasomotor symptoms market will evolve toward precision-based menopause management, integrating AI-driven patient monitoring, hormone-level analytics, and virtual therapy consultations. Asia Pacific and Europe will emerge as high-potential regions due to expanding healthcare access and proactive wellness trends.
Conclusion
The Vasomotor Symptoms Market represents a pivotal opportunity in women's health innovation. With novel non-hormonal drugs entering the market and rising digital-health adoption, the next decade will witness a holistic transformation of menopause-related care.
This report is also available in the following languages : Japanese (血管運動症状市場), Korean (혈관운동증상 시장), Chinese (血管舒缩症状市场), French (Marché des symptômes vasomoteurs), German (Markt für vasomotorische Symptome), and Italian (Mercato dei sintomi vasomotori), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/request-sample/49980
Related Reports
Post-Polycythemia Vera Myelofibrosis Market
https://exactitudeconsultancy.com/reports/71088/post-polycythemia-vera-myelofibrosis-market
Systemic Sclerosis Market
https://exactitudeconsultancy.com/reports/71330/systemic-sclerosis-market
Argininosuccinic Aciduria Market
https://exactitudeconsultancy.com/reports/71682/argininosuccinic-aciduria-market
Familial Adenomatous Polyposis Market
https://exactitudeconsultancy.com/reports/71689/familial-adenomatous-polyposis-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Vasomotor Symptoms Market to Reach USD 12.1 Billion by 2034 here
News-ID: 4266222 • Views: …
More Releases from Exactitude Consultancy
Hepatitis B Treatment Market to Surpass USD 7.85 Billion by 2034
Pune, India, November 2025 - According to the latest report from Exactitude Consultancy, the Global Hepatitis B Treatment Market is valued at USD 5.1 billion in 2024 and is projected to reach USD 7.85 billion by 2034, growing at a CAGR of 4.3% between 2025 and 2034. This growth is driven by the increasing global incidence of chronic hepatitis B infections, improved diagnostic access, and innovative treatment pipelines targeting viral…
Insulin Biosimilars Market to Reach USD 8.9 Billion by 2034
Pune, India, November 11, 2025 - The global Insulin Biosimilars Market is projected to grow from USD 5.4 billion in 2024 to USD 8.9 billion by 2034, registering a CAGR of 5.1 %, according to Exactitude Consultancy. Rising prevalence of diabetes, increasing pressure for cost-effective biologics, and patent expirations of leading insulin brands are driving a wave of biosimilar approvals worldwide.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/49977
Key…
COVID-19 Sample Collection Kits Market to Reach USD 4.3 Billion by 2034
Pune, India, November 11, 2025 - The global COVID-19 Sample Collection Kits Market is projected to rise from USD 2.9 billion in 2024 to USD 4.3 billion by 2034, growing at a CAGR of 4.0 %, according to Exactitude Consultancy. Even as COVID-19 evolves into an endemic virus, continued focus on disease surveillance, multiplex respiratory testing, and rapid sample logistics keeps demand strong for standardized, high-integrity sample-collection consumables.
Download Full PDF…
Mechanical Ventilators Market to Reach USD 7.6 Billion by 2034
Pune, India, November 11, 2025 - The global Mechanical Ventilators Market is projected to rise from USD 5.2 billion in 2024 to USD 7.6 billion by 2034, registering a CAGR of 3.9 %, according to Exactitude Consultancy. Increasing incidence of chronic respiratory diseases, aging populations, and ICU expansions across developing nations are driving sustained investment in critical-care ventilator systems and portable respiratory devices.
Download Full PDF Sample Copy of Market Report…
More Releases for Vasomotor
Menopausal Population Growth Fuels Expansion Of Vasomotor Menopausal Symptoms Tr …
Which drivers are expected to have the greatest impact on the over the vasomotor menopausal symptoms (vms) treatment market's growth?
The rise in the population of menopausal women is predicted to drive the vasomotor menopausal symptom's treatment market expansion. Menopause, a natural system marking the conclusion of reproductive years in a woman, typically takes place between the ages of 45 and 55, with the average age being roughly 51. The increase…
Vasomotor Symptoms Market Trends, Size, Share & Forecast
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Vasomotor Menopausal Symptoms (VMS) Treatment Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $23.11 billion…
The Comprehensive Guide to the Vasomotor Symptoms Treatment Market
Welcome to our comprehensive exploration of the Vasomotor Symptoms Treatment Market, a rapidly evolving sector within healthcare. In this extensive article, we will provide a detailed analysis of various aspects of this market, including its overview, dynamics, external trends, segmentation, growth drivers, recent developments, hydrogel dressing analysis, competitor landscape, key players, and an extensive list of frequently asked questions (FAQs).
Get a Free Sample Report with a Table of Contents@ https://www.expertmarketresearch.com/reports/vasomotor-symptoms-treatment-market/requestsample
Vasomotor Symptoms…
Vasomotor SymptomsTherapeutics: Unveiling New Drug Prospects and Market Predicti …
The Estetrol market forecast report provides analysis of Estetrol market analysis and forecasts upto 2032 in the major markets. The comprehensive report provides analysis of Estetrol market potential and Estetrol market share analysis in Vasomotor Symptoms across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2019 to 2032. It helps you to understand the Estetrol mechanism of action, route of administration, dosage and…
Vasomotor Symptoms of Menopause Market to be at Forefront by 2024
Menopause is the stage during which women stop producing ovaries and there is an end of the fertile phase. It occurs in 85% of premenopausal women during their late 40s, resulting in the cessation of their menstrual cycle. Due to the cessation of menstrual flow, the production of estrogen decreases and gonadotropin increases, which gives rise to various physiological and psychological changes, called vasomotor symptoms. Vasomotor symptoms of menopause are…
Vasomotor Symptoms of Menopause Market Share by Industry Research 2016 - 2024
Global Vasomotor Symptoms of Menopause Market: Overview
Menopause is the stage during which women stop producing ovaries and there is an end of the fertile phase. It occurs in 85% of premenopausal women during their late 40s, resulting in the cessation of their menstrual cycle. Due to the cessation of menstrual flow, the production of estrogen decreases and gonadotropin increases, which gives rise to various physiological and psychological changes, called vasomotor…
